A Rapid Handheld Diagnostic Device for SARS-CoV-2 in Patient Saliva Samples
OmniVis Inc., San Francisco, California, United States
Diagnostic technologies for identification of SARS-CoV-2 from human nasal, buccal, or saliva samples
Tech Brief: OmniVis has a handheld device to detect for the COVID-19 causing pathogen from patient saliva, in under 30 minutes, anywhere in the world. Our handheld platform acts like the portable laboratory to analyze a single use disposable test kit that can be operated by someone without any scientific background.
Early-stage Startup (Seed)
FIGURES OF MERIT Value Proposition: OmniVis technology is half the start-up cost of a traditional GIS mapping system  and 1/10 the cost per test (including cost for materials and labor hours) for COVID-19 pathogen detection ($13 vs. $125 for no prescription), has greater turnaround time (30 minutes compared to results in >24 hours), has automated disease tracking, and can be performed outside of the laboratory space and in the field. Our product provides value with a solution that is: Rapid: outputs result within 30 minutes of data collection, which is < 24-hour turnaround time often found for COVID-19 testing methods - Accurate: Accuracy >90% for COVID-19 in saliva samples - Cost effective: device costs $1,000 for the hardware (1/2 start-up cost) and $15 per test kit (~1/10th cost/test) - Scalable: allows for detection of SARS-CoV-2 through viscosity measurements and has potential for use in other pathogen diagnostics (V. cholerae, S. aureus, K. pneumoniae, E. coli, malaria) - Portable: the device is easily maneuverable and can fit in someone’s hand - Automated: removes the training needed to interpret results - Location specific: automates record keeping and provides real-time data aggregation for outbreak surveillance